Welcome to our dedicated page for ORGANON & CO SEC filings (Ticker: OGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Organon & Co. (NYSE: OGN) provide detailed, regulatory-grade insight into the operations of a global healthcare company focused on Women’s Health, General Medicines and biosimilars. Through current reports on Form 8-K and related amendments, Organon discloses quarterly earnings information, leadership changes, governance matters and the status of internal controls over financial reporting.
Recent 8-K filings furnish earnings releases for quarters such as the period ended June 30, 2025 and September 30, 2025, along with investor presentations that discuss revenue by segment, non-GAAP measures like Adjusted EBITDA and Adjusted gross margin, and capital allocation decisions including dividends. These filings help readers understand how Organon’s women’s health, biosimilars and established brands portfolios contribute to overall performance.
Other 8-Ks and an 8-K/A detail material governance events, including the resignation of the Chief Executive Officer, the appointment of an Interim Chief Executive Officer and an Executive Chair, and compensation arrangements for these roles. Filings also summarize the Audit Committee investigation into wholesaler sales practices for Nexplanon, the determination that certain practices were improper, and the conclusion that previously issued financial statements do not require restatement, while management’s prior assessment of internal control effectiveness must be revised.
On this page, users can review Organon’s SEC disclosures alongside AI-powered summaries that clarify the significance of each document. Filings such as earnings 8-Ks, future annual reports on Form 10-K, quarterly reports on Form 10-Q and any proxy or insider transaction reports can be examined to track segment performance, internal control remediation, leadership structure and other regulatory matters. Real-time updates from EDGAR combined with AI explanations can help investors and researchers interpret complex language, identify key risk and governance themes, and follow Organon’s ongoing reporting obligations.
Organon & Co. insider corrects a prior Form 4 filing related to a tax-withholding share sale. The officer, listed as Interim Head of Manufacturing & Supply, clarifies that a November 7, 2025 transaction involving 1,242 shares of Organon common stock at $6.71 per share (transaction code F) should have been reported as a disposal rather than an acquisition. This transaction reflects shares sold to satisfy a tax liability arising from the acquisition of other Organon shares. After properly classifying the sale, the officer’s beneficial ownership is reported as 17,174.703 shares of Organon common stock held directly.
Organon & Co. reported an equity grant to a senior officer through a Form 4 filing. Interim Head of Manufacturing & Supply Juliana Drinane received an award of 65,616 restricted stock units (RSUs) on November 13, 2025. Each RSU converts into one share of Organon common stock, so this grant represents 65,616 potential future shares. The RSUs will vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028, aligning the officer’s compensation with the company’s longer-term performance.
Organon & Co. reported an equity grant to its interim CEO. On November 13, 2025, officer and interim CEO Joseph T. Morrissey, Jr. received 131,233 restricted stock units (RSUs), each convertible into one share of Organon common stock. The RSUs were granted following the company’s earnings release for the quarter ended September 30, 2025. These RSUs vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028. After this grant, Morrissey beneficially owns 131,233 derivative securities directly.
Organon & Co. (OGN) reported an insider purchase on a Form 4. Executive Chair and Director Carrie Smith Cox bought 65,400 shares of common stock on 11/12/2025 at a $7.6721 weighted average price.
The filing notes the shares were acquired in multiple trades within a price range of $7.6630 to $7.6899. Following the transaction, Cox beneficially owned 77,869 shares, held indirectly through an IRA.
Organon & Co. (OGN) reported insider activity by officer Juliana Drinane (Interim Head of Mfg & Supply). On 11/07/2025, 3,626 restricted stock units converted into common stock at $0 per share (transaction code M). The filing also lists a transaction coded F for 1,242 shares at $6.71 per share on the same date. Following the reported transactions, direct beneficial ownership is shown as 19,658.703 common shares.
The RSUs derived from a grant of 10,876 units awarded on November 7, 2023, vesting in three equal annual installments, with the final vesting date on November 7, 2026. Each RSU represents a right to receive one share of Organon common stock.
Organon & Co. (OGN) filed a Form 3 for an officer serving as Interim Head of Mfg & Supply. The report shows 14,790.703 shares of common stock held directly.
It also lists restricted stock units (each RSU equals one share) covering common stock: 6,378 (exercisable 03/31/2025; final vesting 03/31/2026), 7,252 (11/07/2025; 11/07/2026), 15,958 (03/29/2026; 03/29/2027), and 30,221 (03/31/2026; 03/31/2028). The event date is 10/27/2025.
Organon & Co. (OGN): Insider equity update. On 11/07/2025, the Head of R&D & CMO reported the conversion of restricted stock units into 6,446 shares of common stock at $0 per share (code M). To cover taxes, 2,307 shares were withheld at $6.71 per share (code F). Following these transactions, direct beneficial ownership is 28,916.355 shares.
The filing notes an RSU grant vesting in three installments: 6,446 shares on November 7, 2024; 6,446 shares on November 7, 2025; and 6,447 shares on November 7, 2026. After the reported activity, 6,447 RSUs remain outstanding, expiring on November 7, 2026.
Organon (OGN) SVP and Corporate Controller reported Form 4 activity. On 11/07/2025, 2,417 shares of common stock were acquired at $0 via the conversion of restricted stock units (code M). The filer also disposed of 689 shares at $6.71 (code F). Following these transactions, beneficial ownership stands at 14,676.427 shares (direct).
The related RSU entry shows 2,417 underlying shares converted, with 2,418 RSUs remaining directly beneficially owned. The original grant was 7,252 RSUs on 11/07/2023, vesting one‑third each year through 11/07/2026.
Organon & Co. reported Q3 2025 results with revenues of $1,602 million, up slightly from $1,582 million a year ago. Gross profit was $857 million. Net income was $160 million and diluted EPS was $0.61, compared with $359 million and $1.38 in Q3 2024. The effective tax rate was 34.0%.
Year to date, revenues were $4,709 million versus $4,811 million last year, with net income of $392 million. Operating cash flow reached $559 million for the first nine months. The company ended the quarter with cash and equivalents of $672 million, total assets of $13,552 million, long-term debt of $8,783 million, and stockholders’ equity of $906 million. In Q2 2025, Organon repurchased $242 million of 5.125% notes due 2031 and terminated a $103 million NovaQuest funding agreement, recording gains in other income.
Product highlights included Nexplanon/Implanon NXT $223 million and Vtama $34 million in the quarter. In September, the FDA approved Bildyos and Bilprevda (denosumab biosimilars) for all reference indications, with the EU also granting authorizations. The company declared a $0.02 per-share dividend in Q3 and reported a restructuring program initiated earlier in 2025.
Organon & Co. (OGN) furnished its quarterly update. The company provided a press release covering results for the quarter ended September 30, 2025 and an investor presentation, both made available on November 10, 2025. The press release is attached as Exhibit 99.1 and the presentation as Exhibit 99.2. These materials are furnished, not filed, and include forward-looking statements with related cautions.